SLC5A2 and heart failure: Subgroup analysis further confirmed that these improvements were primarily observed in patients with heart failure or those receiving empagliflozin treatment.[14] Our study specifically investigated the impact of SGLT2 inhibitors on left ventricular structure and function in patients diagnosed with NIDCM.